XGN
ExagenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bullish read is that Exagen is showing a real commercial-improvement pattern: Q1 2026 delivered record revenue, 12% year-over-year growth, 10% AVISE CTD volume growth, higher ASP, and better adjusted EBITDA, while full-year guidance was maintained. That combination supports a cautious rerating case if Q2 confirms the gains are repeatable.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.8.
What can break
Failure to sustain AVISE CTD volume and ASP gains could quickly pressure the current improvement narrative.
Momentum
51
Value
41
Sentiment
69
Setup hits (3d)
— · Net —
AI TargetsBase $5.75 · Bull $7.50 · Bear $3.20
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $8.57
Why
Momentum51 · Δ7d -4.0
Value41 · Δ7d -0.1
Sentiment69 · Δ7d +8.8
So what
Balanced signals. Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
51
26% active weight
Current posture
7d trendSoftening
Δ7d
-4.0
Δ21d
-22.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
69
34% active weight
Current posture
7d trendImproving
Δ7d
+8.8
Δ21d
-13.9
Why this grade
Composite grade C. Momentum 50.5 / Value 41.1 / Sentiment 69.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$106.06M
Beta
1.91
Shares Out
24.16M
P/E (TTM) · Derived
-4.7
P/S (TTM)
2.12
P/FCF (TTM) · Derived
-7.24
Rev YoY
+11.7%
EPS YoY
-17.8%
Gross Margin
+58.3%
Op Margin
-20.1%
Net Debt
-$4.55M
Current Ratio
3.47
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology